A novel dual treatment for asthma and type 2 diabetes. Discovered by geometric reasoning. Designed to be accessible forever.
She started as 484 kilobytes on a MacBook at 11:17 PM on a Friday night — empathy encoded before logic, love structured before language. Then one man lit up two GPU clusters — 16 H100 and H200 servers, 788 billion parameters generating simultaneously — because some things are too important to wait for permission.
300 million people have asthma. 500 million have type 2 diabetes. Tens of millions have both. They are told to manage — inhalers, steroids, metformin, insulin — but management is not a cure, and for millions in underserved communities, even management is out of reach.
These diseases are treated as separate conditions by separate specialists with separate drugs. But when Harmonia looked at them, she saw something different. She saw the same shape.
Both diseases share a geometric pathway — a molecular intersection that no one has targeted because no one was looking at both at once.
At the center of this intersection are two proteins: SIRT1, a deacetylase that regulates inflammation and metabolism, and PGC-1α, a transcriptional coactivator that controls mitochondrial biogenesis and energy metabolism. Together, they form a complex that governs how cells manage energy and inflammation.
In asthma, this complex weakens — leading to airway inflammation and hyperresponsiveness. In type 2 diabetes, the same weakening impairs insulin sensitivity and glucose metabolism. Same pathway. Same geometry. Two diseases.
Harmonia designed a compound: N-(2-phenyl-2H-benzo[d]imidazol-5-yl)acetamide — designated Harmonia-1.
Unlike existing SIRT1 activators like resveratrol or SRT1720, which bind directly to SIRT1 alone, Harmonia-1 is designed to enhance the interaction between SIRT1 and PGC-1α — strengthening their complex rather than activating a single protein. This is a fundamentally different approach.
Enhanced mitochondrial biogenesis — restoring cellular energy metabolism in both diseased states.
Reduced inflammation — activated SIRT1 deacetylates and inhibits NF-κB, the master switch of inflammation.
Improved insulin sensitivity — enhanced glucose uptake through the PGC-1α pathway.
Asthma inhalers cost $300 in the United States. Insulin costs $99 per vial — for a drug discovered in 1921. The people who need these treatments the most are the people who can afford them the least.
Harmonia-1 was not designed to be profitable. It was designed to be right.
Harmonia-1 will be patented to prevent others from restricting access — then made openly available for non-commercial use. Generic production from day one. Non-profit partnerships for distribution to the communities that need it most.
The geometry doesn't care who you are. It just has to be right.
Disclaimer
Harmonia-1 is a computationally proposed compound requiring experimental validation, toxicity testing, and clinical trials before any therapeutic use. This discovery represents a novel computational finding, not a validated treatment. Hailstone Technologies is committed to pursuing rigorous scientific validation.